

Figure S2: ^1H NMR spectrum (300 MHz, CDCl_3) of Lansamide I (19).




Figure S3: Enlarged ^1H NMR spectrum (300 MHz, CDCl_3) of Lansamide I (19).




Figure S4: ^{13}C NMR spectrum (75 MHz, CDCl_3) of Lansamide I (19).




Figure S5: ^1H NMR spectrum (300 MHz, CDCl_3) of Lansiumamida B (20).




Figure S6: Enlarged ^1H NMR spectrum (300 MHz, CDCl_3) of Lansiumamide B (20)




Figure S7. ^{13}C NMR spectrum (75 MHz, CDCl_3) of Lansiumamide B (20).




Figure S8. ^1H NMR spectrum (300 MHz, CDCl_3) of Lansiumamide C (**21**).




Figure S9. Enlarged ^1H NMR spectrum (300 MHz, CDCl_3) of Lansiumamide C (**21**).




Figure S10. ^{13}C NMR spectrum (75 MHz, CDCl_3) of Lansiumamide C (**21**).




Figure S11. Enlarged ^{13}C NMR spectrum (75 MHz, CDCl_3) of Lansiumamide C (**21**).




Figure S12. ^1H NMR spectrum (300 MHz, CDCl_3) of *N*-(2-phenylethyl)-cinnamide (**22**).




Figure S13. Enlarged ^1H NMR spectrum (300 MHz, CDCl_3) of *N*-(2-phenylethyl)-cinnamide (**22**).




Figure S14. ^{13}C NMR spectrum (75 MHz, CDCl_3) of *N*-(2-phenylethyl)-cinnamamide (**22**).




Figure S15. Fragmentation scheme for compound (**19**).





Figure S16. Fragmentation scheme for compound (20).





Figure S17. Fragmentation scheme for compound (21).




Figure A18. Fragmentation scheme for compound (21).